Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical pharmacology study of tofogliflozin in patients with hepatic impairment
jRCT2080221650Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tofogliflozin in hepatic impairment (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary pharmacokinetic endpoints.
02
Drugs
tofogliflozin
03
Conditions
hepatic impairment
Beyond the preview
Go deeper on jRCT2080221650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221650.